

Contents

[Editors](#)
[Contributors](#)
[Introduction](#)

SECTION I Background and Epidemiology

- [1. History of the European Society of Hypertension: Past, Present and Future](#)
Konstantinos P. Tsioufis and Enrico Agabiti-Rosei
- [2. Hypertension as a Cardiovascular Risk Factor](#)
Renata Cifkova and Peter J. Blankestijn
- [3. Hypertension and the Kidney](#)
Roberto Pontremoli, Giovanna Leoncini and Francesca Viazzi
- [4. Blood Pressure Control in Europe and Elsewhere](#)
Josep Redon, Gernot Pichler and Fernando Martinez
- [5. Socioeconomic Determinants](#)
Theodora Psaltopoulou and Theodoros N. Sergentanis

SECTION II Etiological and Pathophysiological Aspects

- [6. Hemodynamic Patterns in Hypertension](#)
Per Omvik and Per Lund-Johansen

7. Genetic Basis of Blood Pressure and Hypertension
Sandosh Padmanabhan, Alisha Aman and Anna F. Dominiczak
8. Oxidative Stress, Inflammation, Immune System and Hypertension
Damiano Rizzoni, Livia L. Camargo, Francisco J. Rios, Augusto C. Montezano and Rhian M. Touyz
9. Sodium and Potassium
Lanfranco D'Elia and Pasquale Strazzullo
10. Structural Cardiovascular Changes in Hypertension
M. Mulvany, Enrico Agabiti-Rosei and H. Struijker-Boudier
11. Early Vascular Ageing
Peter M. Nilsson and Stéphane Laurent
12. Autonomic Dysfunction
Gino Seravalle and Guido Grassi
13. The Renin–Angiotensin–Aldosterone System
Ulrike M. Steckelings and Thomas Unger
14. Stress, Stress Reduction and Hypertension: An Updated Review
Komal Marwaha and Robert H. Schneider

SECTION III Associated Risk Factors: Pathogenetic Role and Risk Modification

15. Heart Rate as a Cardiovascular Risk Factor in Hypertension
Paolo Palatini
16. Obesity and Obstructive Sleep Apnoea
Dagmara Hering, Jacek Wolf, Marzena Chrostowska and Krzysztof Narkiewicz
17. The Metabolic Syndrome in Hypertension
Josep Redon, Fernando Martinez and Gernot Pichler
18. Psychosocial Risk Factors, Airborne Pollution, Hypertension and Cardiovascular Diseases
Philippe van de Borne
19. Serum Uric Acid, Blood Pressure and Hypertension
Claudio Borghi

20. Dyslipidaemia in Hypertension

Massimo Volpe, Giovanna Gallo and Giuliano Tocci

SECTION IV Blood Pressure Measurements

21. Old and New Office Blood Pressure Measurement Approaches

Michael Bursztyrn and Iddo Z. Ben-Dov

22. Pulse Pressure

Pierre Boutouyrie and James E. Sharman

23. Central Blood Pressure

Stéphane Laurent and Cristina Giannattasio

24. Ambulatory Blood Pressure Measurement

Eoin O'Brien, Eamon Dolan and Jan Staessen

25. Home Blood Pressure

George S. Stergiou and Anastasios Kollias

26. Day-Night Related Events: Nighttime Blood Pressure Fall and Morning Blood Pressure Rise

Fabio Angeli, Gianpaolo Reboldi, Monica Trapasso and Paolo Verdecchia

27. Short-Term Blood Pressure Variability

Gianfranco Parati, Thomas F. Luscher and Juan Eugenio Ochoa

28. Exercise Blood Pressure: The Prognostic Impact of Exercise Systolic Blood Pressure

Julian E. Mariampillai, Per Torger Skretteberg, Sverre E. Kjeldsen, Johan Bodegård and Jan E. Erikssen

SECTION V Organ Damage- Measurement/Clinical Value

29. Cardiac Damage from Left Ventricular Hypertrophy to Heart Failure

Enrico Agabiti-Rosei, Maria Lorenza Muiesan and Cesare Cuspidi

30. Structural and Functional Aspects of Brain Damage

Cristina Sierra, Miguel Camafort and Antonio Coca

31. Large Artery Damage: Measurement and Clinical Importance
Stéphane Laurent and Michel E. Safar
32. Microcirculation
Reza Aghamohammadzadeh and Anthony M. Heagerty
33. Endothelial Damage
Stefano Masi, Rosa Maria Bruno, Lorenzo Ghiadoni, Agostino Virdis and Stefano Taddei
34. Retinal Changes
A. Bosch and Roland E. Schmieder

SECTION VI Integrated Diagnostic Aspects

35. The Integrated Diagnostic Approach in General Medicine
Andrzej Więcek, Aleksander Prejbisz and Andrzej Januszewicz
36. Management of Hypertension by the Hypertension Specialist and the Hypertension Excellence Centres
Bojan Jelaković

SECTION VII Therapeutic Aspects

37. Non-Pharmacological Interventions
Stefan Engeli and Jens Jordan
38. The Protective Cardiovascular Effects of Antihypertensive Treatment
Alberto Zanchetti (Late) and Costas Thomopoulos
39. The Nephroprotective Effect of Antihypertensive Treatment
Luis M. Ruilope and Jose R. Banegas
40. Antihypertensive Drug Classes
Engi Abdel-Hady Algharably and Reinhold Kreutz
41. Single-Pill Combination Treatments in Hypertension
Michel Burnier
42. The J-Curve Phenomenon
Louis Hofstetter and Franz H. Messerli

43. A Polypill for Global Cardiovascular Prevention: Current Data and Future Perspectives

José Maria Castellano, Mónica Doménech and Antonio Coca

44. Managing Adverse Effects and Drug Intolerance

Nikitas Alexander P. Skliros, Antonios A. Argyris and Athanase D. Protogerou

45. Adherence to Treatment in Hypertension

Michel Burnier

46. Residual Risk in Treated Patients

Giuseppe Mancia

SECTION VIII SpecialConditions

47. Ethnic Factors in Hypertension

Katarzyna Stolarz-Skrzypek, Danuta Czarnecka and Andrzej Januszewicz

48. Resistant Hypertension: Medical Treatment

Michel Azizi, Laurence Amar, Aurélien Lorthioir and Anne-Marie Madjalian

49. Interventional Therapies for Essential Hypertension

Konstantinos P. Tsioufis, Kyriakos Dimitriadis, Alex Kasiakogias and Vassilios Papademetriou

50. Atrial Fibrillation and Arterial Hypertension

D.E. Athanasiou, M.S. Kallistratos, L.E. Poulimenos and A.J. Manolis

51. The Diabetic/Obese Hypertensive Patient (Including Metabolic Syndrome)

Vasilios Kotsis

52. Hypertension in Children and Adolescents

Empar Lurbe and Pau Redon

53. Hypertensive Emergencies and Urgencies

Maria Lorenza Muiesan, Anna Paini, Claudia Agabiti-Rosei, Fabio Bertacchini and Massimo Salvetti

54. Hypertension Associated with Peripheral Artery Disease

Denis L. Clement

55. Hypertension in Pregnancy

Renata Cífková

56. [Drug-Induced Hypertension](#)
Gurvinder Rull and Melvin D. Lobo
57. Hypertension in Patients with Advanced Chronic Kidney Disease
Charalampos Loutradis and Pantelis Sarafidis
58. Blood Pressure Management in Acute Stroke
Efstathios Manios, Eleni Koroboki and Konstantinos Vemmos
59. Blood Pressure Management in the Chronic Post-Stroke Phase
Hisatomi Arima and John Chalmers
60. [The Post-Transplant Patient with Hypertension](#)
Martin Hausberg and Karl Heinz Rahn

[SECTION IX Secondary Hypertension: Diagnosis and Treatment](#)

61. Renovascular Hypertension
Peter W. de Leeuw and Alberto Morganti
62. [Primary Aldosteronism](#)
Gian Paolo Rossi
63. Pheochromocytoma and Paraganglioma
Andrzej Januszewicz, Jacques W.M. Lenders, Graeme Eisenhofer and Aleksander Prejbisz

SECTION X Additional Aspects

64. [Follow-Up of the Hypertensive Patient](#)
Michael Dumas, Konstantinos Stavropoulos, Gemma Currie and Christian Delles
65. 2018 ESC/ESH Hypertension Guidelines
Bryan Williams, Giuseppe Mancia, Wilko Spiering, Enrico Agabiti-Rosei, Michel Azizi, Michel Burnier, Denis L. Clement, Antonio Coca, Giovanni de Simone, Anna F. Dominiczak, Thomas Kahan, Felix Mahfoud, Josep Redon, Luis M. Ruilope, Alberto Zanchetti, Mary Kerins, Sverre E. Kjeldsen, Reinhold Kreutz, Stephane Laurent, Gregory Y.H. Lip, Richard McManus, Krzysztof Narkiewicz, Frank Ruschitzka, Roland E. Schmieder, Evgeny Shlyakhto, Konstantinos P. Tsioufis, Victor Aboyans and

HYPERTENSION AS A CARDIOVASCULAR RISK FACTOR

2

Renata Cifkova and Peter J. Blankestijn

HYPERTENSION AS A CARDIOVASCULAR RISK FACTOR

Hypertension is the most prevalent cardiovascular disorder, affecting 20–50% of the adult population worldwide, and ranking, in a comparative risk assessment of 84 risk factors and risk factor clusters, high for global disease burden (1). Likewise, it has been identified as a risk factor for coronary heart disease, stroke, peripheral arterial disease and heart and renal failure in both men and women in a large number of epidemiological studies (2–5). Hypertension has also been shown to increase the risk of atrial fibrillation (6). In addition, observational studies have found that blood pressure (BP) correlates inversely with cognitive function and that hypertension is associated with an increased incidence of dementia (7,8).

In the year 2001, the worldwide burden of disease attributable to high systolic BP (≥ 115 mmHg) was 54% for stroke, and 47% for ischaemic heart disease (9). About half of this burden was experienced by individuals with hypertension, the other part in those with a lesser degree of high BP. More than 80% of the attributable burden of the disease was found in low- and middle-income regions.

A meta-analysis of individual data of one million adults from 61 prospective observational studies found a continuous graded independent relationship with the risk of stroke and coronary events (10). Coronary heart disease (CHD) and stroke mortality increases progressively and linearly from BP levels as low as 115 mmHg systolic and 75 mmHg diastolic upward (Figures 2.1 and 2.2). The increased risks are seen in all age groups from 40 to 89 years of age.

For every 20 mmHg systolic or 10 mmHg diastolic BP increase, there is a doubling of mortality from CHD and stroke.




Figure 2.1 Stroke mortality rate in each decade of age plotted for the usual systolic (a) and diastolic (b) blood pressure at the start of that decade. Data from 1 million adults in 61 prospective studies. (Adapted from Lewington S et al. *Lancet* 2002; 360(10): 1903–1913.)




Figure 2.2 Ischaemic heart disease (IHD) mortality rate in each decade of age plotted for the usual systolic (a) and diastolic (b) blood pressure at the start of that decade. Data from one million adults in 61 prospective studies. (Adapted from Lewington S et al. *Lancet* 2002; 360(10): 1903–1913.)

ASSESSMENT OF TOTAL CARDIOVASCULAR RISK IN HYPERTENSION

INTRODUCTION

Historically, hypertension guidelines long focused on BP values as the only or main variables determining therapeutic interventions. Although this approach was maintained in the 2003 Joint National Committee (JNC) seven guidelines (11) and was found cost effective (12), the ESH-ESC guidelines have since 2003 (13–15) emphasized that management of hypertension should be related to quantification of total cardiovascular (CV) risk. Finally, this approach was also adopted by the most recent US hypertension guidelines (16). The rationale for this approach is that only a small proportion of the hypertensive population has an elevation of BP alone with the great majority exhibiting additional CV risk factors (17–21), with a relationship between the severity of BP elevation and that of alterations in glucose and lipid metabolism (22). When elevated BP and metabolic risk factors are concomitantly present, they potentiate each other risk (17,23,24). Thresholds and goals for antihypertensive treatment as well as treatment strategies for

concomitant risk factors may differ based on total CV risk. Therefore, estimation of total CV risk is essential for guiding patient management.

The use of total CV risk estimation may also improve physicians' behaviour in drug prescription and patient adherence (25,26); however, there are some reports showing no impact on provider behaviours (27) and inadequate use in routine clinical practice (28,29).

HOW TO ASSESS TOTAL CV RISK

A number of complex and computerized methods have been developed for estimating total CV risk, that is, the likelihood of experiencing a CV event, usually within the next 10 years. Many risk stratification systems are based on the Framingham study (30), estimating the 10-year risk for both fatal and nonfatal CHD by systolic BP and presence of other risk factors. The easy and rapid calculation of the Framingham risk score using published tables (National Cholesterol Education Program [NCEP]) (31) may assist the physician and patient in demonstrating the benefits of treatment.

The Framingham risk stratification has been shown to be reasonably applicable to some European populations (32) but requiring recalibration in other populations (33,34) due to geographic differences in the incidence of coronary and stroke events.

The latest US hypertension guidelines (16) recommend use of the ACC/AHA Pooled Cohort Equation (<http://tools.acc.org/ASCVD-Risk-Estimator/>) to estimate the 10-year risk of atherosclerotic CVD (ASCVD) to establish the BP threshold for treatment (35).

Given the need for a European model based on a large database, the SCORE (Systemic Coronary Risk Evaluation) project (36) was used to develop SCORE charts for high- and low-risk countries in Europe estimating the risk of dying from CV (not just coronary) disease over 10 years, and allowing calibration of the charts for individual countries provided that national mortality statistics and estimates of the prevalence of major CV risk factors are available. The SCORE model has also been used in the HeartScore, the official European Society of Cardiology management tool for implementation of CVD prevention in clinical practice (<http://www.escardio.org>).

The main disadvantage associated with an intervention threshold based on relatively short-term absolute risk is that younger adults (particularly women), while having more than one risk factor, are unlikely to reach treatment thresholds despite being at high risk relative to their peers. By contrast, most elderly men (e.g., those aged 65) will often reach treatment thresholds whilst being at very little increased risk relative to their peers. This situation results in most resources being concentrated on the oldest subjects whose potential

lifespan, despite intervention, is relatively limited, while young subjects at high relative risk remain untreated despite, in the absence of intervention, a predicted significant shortening of their otherwise much longer potential lifespan (37,38).

Use of the SCORE chart for estimating total CV risk in hypertension should be considered a minimal requirement taking into account the fact that total CV risk can be underestimated (39).

On the basis of these considerations, the 2013 ESH-ESC guidelines (15) suggest total CV risk be stratified as shown in Table 2.1. The terms *low* (<1%), *moderate* (≥ 1 and <5%), *high* (≥ 5 and <10%) and *very high* ($\geq 10\%$) risk refer to the 10-year risk of CV mortality as defined by the 2012 ESC prevention guidelines (40). The factors on which this stratification is based are listed in Table 2.2. They include risk factors, asymptomatic organ damage, diabetes mellitus and established CV or renal disease.

Table 2.1 Stratification of total CV risk

Other risk factors, asymptomatic organ damage or disease	Blood pressure (mmHg)			
	High normal SBP 130–139 or DBP 85–89	Grade 1 HT SBP 140–159 or DBP 90–99	Grade 2 HT SBP 160–179 or DBP 100–109	Grade 3 HT SBP ≥ 180 or DBP ≥ 110
No other RF		Low risk	Moderate risk	High risk
1–2 RF	Low risk	Moderate risk	Moderate to high risk	High risk
≥ 3 RF	Low to moderate risk	Moderate to high risk	High risk	High risk
OD, CKD stage 3 or diabetes	Moderate to high risk	High risk	High risk	High to very high risk
Symptomatic CVD, CKD stage ≥ 4 or diabetes with OD/RFs	Very high risk	Very high risk	Very high risk	Very high risk

BP = blood pressure; CKD = chronic kidney disease; CV = cardiovascular; CVD = cardiovascular disease; DBP = diastolic blood pressure; HT = hypertension; OD = organ damage; RF = risk factor; SBP = systolic blood pressure.

Table 2.2 Factors – other than office BP – influencing prognosis; used for stratification of total CV risk

Risk factors

- Male sex
- Age (men ≥ 55 years; women ≥ 65 years)
- Smoking
- Dyslipidemia
 - Total cholesterol >4.9 mmol/L (190 mg/dL); and/or
 - LDL-cholesterol >3.0 mmol/L (115 mg/dL); and/or
 - HDL-cholesterol: men <1.0 mmol/L (40 mg/dL), women <1.2 mmol/L (46 mg/dL); and/or
 - Triglycerides >1.7 mmol/L (150 mg/dL)
- Fasting plasma glucose 5.6–6.9 mmol/L (102–125 mg/dL)
- Abnormal glucose tolerance test
- Obesity (BMI ≥ 30 kg/m²)
- Abdominal obesity (waist circumference: men ≥ 102 cm, women ≥ 88 cm in Caucasians)
- Family history of premature CV disease (men aged <55 years; women aged <65 years)

Asymptomatic organ damage

- Pulse pressure (in the elderly) ≥ 60 mmHg
- Left ventricular hypertrophy
 - Electrocardiogram: Sokolow-Lyon index >3.5 mV; RaVL >1.1 mV; Cornell voltage duration product >244 mV x ms; or
 - Echocardiogram: LVM index^a: men >115 g/m²; women >95 g/m²
- Carotid wall thickening (IMT >0.9 mm) or plaque
- Carotid-femoral pulse wave velocity >10 m/s
- Ankle-brachial index <0.9
- CKD with eGFR (30–60 mL/min/1.73 m²)
- Microalbuminuria
30–300 mg/24 h or albumin-creatinine ratio 30–300 mg/g; 3.4–34 mg/mmol preferentially in morning spot urine

Diabetes mellitus

- Fasting plasma glucose ≥ 7.0 mmol/L (126 mg/dL) on 2 repeated measurements; and/or
- HbA_{1c} $>7\%$ (53 mmol/mol); and/or
- Post-load plasma glucose >11.0 mmol/L (198 mg/dL)

Established CV or renal disease

- Cerebrovascular disease:
 - Ischaemic stroke
 - Cerebral haemorrhage
 - Transient ischaemic attack
- CHD:
 - Myocardial infarction
 - Angina
 - Coronary revascularization with PCI or CABG
 - Heart failure
- Heart failure, including heart failure with preserved EF
- Symptomatic lower extremities PAD
- CKD with eGFR <30 mL/min/1.73 m²; proteinuria (>300 mg/24 h)
- Advanced retinopathy:
 - Haemorrhages or exudates
 - Papilledema

Source: Adapted from Mancia G et al. *J Hypertens* 2013; 31(15): 1281–1357.

Abbreviations: BMI, body mass index; CABG, coronary artery bypass grafting; CHD, coronary heart disease; CKD, chronic kidney disease; CV, cardiovascular; EF, ejection fraction; eGFR, estimated glomerular filtration rate; HbA_{1c}, glycated hemoglobin; HDL-C, high-density lipoprotein cholesterol; IMT, intima-media thickness; LDL-C, low-density lipoprotein cholesterol; LVM, left ventricular mass; PCI, percutaneous coronary intervention; PWV, pulse wave velocity.

^a Risk maximal for concentric LVH: increased LVM index with a wall thickness to radius ratio of 0.42.